Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Ongoing supervision is important for safety
Most clinical studies demonstrate no significant link between GLP-1RA therapy and PDAC
Specifically, GLP-1 use was associated with an 18% lower risk of a composite TED-related diagnosis at one year and a 10% lower risk at three years. This retrospective, population-based cohort study used the TriNetX US Collaborative Network to identify patients with thyroid disease initiating a GLP-1 drug or a non-GLP-1 active control medication
95% CI, 0.74-0.86) compared with those treated with DPP-4 inhibitors
Gastrointestinal side effects are well-documented with GLP-1 therapy and may indirectly affect fluid balance
US$ 27.17
US$ 20.25
US$ 29.85
